Egenesis is a private company building in biotechnology / healthcare, founded in 2015. Investors last valued the company at $350M. Its shares do not trade on a public exchange.
1 valuation. The latest, $350M post-money, was set by the Series C in Feb 2021.
Lux CapitalLEAD
Fresenius Medical Care VenturesLEAD
ARCH Ventures
Khosla Ventures
Farallon CapitalAAlta PartnersLLeaps by BayerDDaVitaEEisai InnovationNNATCO PharmaceuticalsPParkwood CorporationLux CapitalFresenius Medical Care VentureseGenesis develops gene-edited pig organs for human transplant, working to end the shortage of donor kidneys, livers and hearts. Founded in 2015 and based in Cambridge, Massachusetts, the company applies a multiplexed gene-editing platform to overcome rejection and safety barriers in xenotransplantation.
Its lead candidate, EGEN-2784, is an engineered porcine kidney now advancing toward a Phase 1/2/3 trial cleared by the FDA. One patient given EGEN-2784 under an expanded-access program reached nine months of dialysis independence, a record for a gene-edited pig kidney transplant, before later receiving a human donor kidney.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Egenesis.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Egenesis availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Egenesis included.
The closest biotechnology / healthcare peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Egenesis is a private company; its shares do not trade on a public exchange.
The last valuation is $350M.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
